Daiichi Sankyo Company, Limited Appoints New Group Corporate Officers
February 24, 2017 at 02:02 am EST
Share
Daiichi Sankyo Company, Limited announced the appointment of Toshiaki Sai, Member of the Board, Senior Executive Officer, Head of Corporate Strategy Div. as Member of the Board, Senior Executive Officer, Head of Global Brand Strategy Div.; Noriaki Ishida, Executive Officer, Vice President of Corporate Communications Dept., Corporate Management Div. as Executive Officer, Vice President of Corporate Communications Dept., Corporate Strategy & Management Div.; Junichi Koga, Executive Officer, Head of R&D Div. and Vice President of Research Technology Function, and in charge of Biologics as Executive Officer, Head of R&D Div.; Yoshihiro Aoyagi, Corporate Officer, Vice President of Legal Affairs Dept., General Affairs & Human Resources Div. as Executive Officer, Head of Corporate Affairs; Yuichi Kubo, Corporate Officer, Vice President of Business Development & Licensing Dept., Corporate Strategy Div. as Executive Officer, Vice President of Business Development & Licensing Dept.; Kentaro Takamura, Corporate Officer, Vice President of Finance & Accounting Dept., Corporate Management Div. as Corporate Officer, Vice President of Finance & Accounting Dept., Corporate Strategy & Management Div.; Kenji Katsumi, Corporate Officer, Vice President of Corporate Business Management Dept., Corporate Management Div. as Corporate Officer, Vice President of Corporate Affairs & Procurement Dept., Corporate Affairs Div.; Shinichi Tobita, Vice President of Marketing Dept., Sales & Marketing Div. as Corporate Officer, Vice President of Marketing Dept., Sales & Marketing Div.; Hironobu Furuta, Vice President of General Affairs & Procurement Dept., General Affairs & Human Resources Div. as Corporate Officer, Vice President of Human Resources Dept., Corporate Affairs Div.; Takeshi Hamaura, Vice President of CMC Planning Dept., Pharmaceutical Technology Div. as Corporate Officer, Head of Pharmaceutical Technology Div. and Vice President of CMC Planning Dept.; Hideyuki Hirano, Vice President of Sales Planning Dept., Sales & Marketing Div. as Corporate Officer, Vice President of Sales Planning Dept., Sales & Marketing Div.; Shoji Hirashima, Vice President of Corporate Strategy Dept. and Senior Director of Oncology Business Group, Corporate Strategy Div. as Corporate Officer, Vice President of Corporate Business Management Dept., Corporate Strategy & Management Div. All the appointments are effective April 1, 2017.
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
DAIICHI SANKYO CO., LTD. 
